These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 11208254)

  • 1. Overview of recent clinical trials in heart failure: what is the current standard of care?
    Murray DR; Dugan J
    Cardiol Rev; 2000; 8(6):340-7. PubMed ID: 11208254
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The renin-angiotensin-aldosterone system and heart failure.
    Sayer G; Bhat G
    Cardiol Clin; 2014 Feb; 32(1):21-32, vii. PubMed ID: 24286576
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Role of RAAS inhibitors for the treatment of heart failure].
    Murohara T
    Nihon Rinsho; 2012 Sep; 70(9):1577-81. PubMed ID: 23012806
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pathophysiologic role of the renin-angiotensin-aldosterone and sympathetic nervous systems in heart failure.
    Adams KF
    Am J Health Syst Pharm; 2004 May; 61 Suppl 2():S4-13. PubMed ID: 15160833
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interactions between the sympathetic nervous system and the RAAS in heart failure.
    Goldsmith SR
    Curr Heart Fail Rep; 2004 Jul; 1(2):45-50. PubMed ID: 16036024
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novelties in Therapy of Chronic Heart Failure.
    Doimo S; Pavan D
    Heart Fail Clin; 2021 Apr; 17(2):255-262. PubMed ID: 33673949
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination Therapy of Renin Angiotensin System Inhibitors and β-Blockers in Patients with Heart Failure.
    Nochioka K; Sakata Y; Shimokawa H
    Adv Exp Med Biol; 2018; 1067():17-30. PubMed ID: 29542073
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers: what we know and current controversies.
    Moser DK; Biddle MJ
    Crit Care Nurs Clin North Am; 2003 Dec; 15(4):423-37, vii-viii. PubMed ID: 14717387
    [TBL] [Abstract][Full Text] [Related]  

  • 9. What constitutes optimal neurohumoral antagonism in chronic heart failure?
    Tajik AA; Dickstein K
    Heart; 2016 Dec; 102(23):1922-1932. PubMed ID: 27742799
    [No Abstract]   [Full Text] [Related]  

  • 10. Aldosterone, a new appreciation of its role in heart failure.
    Cha AJ; Malecha SE; Judge KW
    Pharmacotherapy; 2000 Sep; 20(9):1107-15. PubMed ID: 10999504
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Renin-angiotensin-aldosterone system inhibitors in heart failure.
    Shearer F; Lang CC; Struthers AD
    Clin Pharmacol Ther; 2013 Oct; 94(4):459-67. PubMed ID: 23852393
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Update on recent clinical trials in congestive heart failure.
    Betkowski AS; Hauptman PJ
    Curr Opin Cardiol; 2000 Jul; 15(4):293-303. PubMed ID: 11139094
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Programs for continuing medical education: B session; 1. The pathophysiology of heart failure--is it the disease of the heart?].
    Kitakaze M
    Nihon Naika Gakkai Zasshi; 2014 Mar; 103(3):681-6. PubMed ID: 24796136
    [No Abstract]   [Full Text] [Related]  

  • 14. Angiotensin receptor blockers and aldosterone antagonists in chronic heart failure.
    Miller AB; Srivastava P
    Cardiol Clin; 2001 May; 19(2):195-202, v. PubMed ID: 11407105
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of RAAS--when is it too much?
    Navarro P; Moskowitz R; Le Jemtel TH
    Curr Heart Fail Rep; 2004 Jul; 1(2):57-64. PubMed ID: 16036026
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The control of adrenergic function in heart failure: therapeutic intervention.
    Clark AL; Cleland JG
    Heart Fail Rev; 2000 Mar; 5(1):101-14. PubMed ID: 16228919
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incidence and outcomes associated with early heart failure pharmacotherapy in patients with ongoing cardiogenic shock.
    van Diepen S; Reynolds HR; Stebbins A; Lopes RD; Džavík V; Ruzyllo W; Geppert A; Widimsky P; Ohman EM; Parrillo JE; Dauerman HL; Baran DA; Hochman JS; Alexander JH
    Crit Care Med; 2014 Feb; 42(2):281-8. PubMed ID: 23982033
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of the renin-angiotensin-aldosterone system in the management of heart failure.
    Rodgers JE; Patterson JH
    Pharmacotherapy; 2000 Nov; 20(11 Pt 2):368S-378S. PubMed ID: 11089708
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Slowing the progression of CHF. Drug therapy to correct neurohormonal abnormalities.
    Ward RP; Anderson AS
    Postgrad Med; 2001 Mar; 109(3):36-8, 41-5. PubMed ID: 11265361
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Beta-blockers and spironolactone in heart failure.
    Kukin ML
    Curr Cardiol Rep; 2000 Mar; 2(2):87-9. PubMed ID: 10980877
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.